The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors
Open accessThe DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Abstract
Diabetes and obesity are growing problems worldwide and are associated with a range of acute and chronic complications, including acute myocardial infarction (AMI) and stroke. Novel anti-diabetic medications designed to treat T2DM, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is), exert beneficial effects on metabolism and the cardiovascular system. However, the underlying mechanisms are poorly understood. GLP-1RAs induce anorexic effects by inhibiting the central regulation of food intake to reduce body weight. Central/peripheral administration of GLP-1RAs inhibits food intake, accompanied by an increase in c-Fos expression in neurons within the paraventricular nucleus (PVN), amygdala, the nucleus of the solitary tract (NTS), area postrema (AP), lateral parabrachial nucleus (LPB) and arcuate nucleus (ARC), induced by the activation of GLP-1 receptors in the central nervous system (CNS). Therefore, GLP-1RAs need to pass through the blood-brain barrier to exert their pharmacological effects. In addition, studies revealed that SGLT-2is could reduce the risk of chronic heart failure in people with type 2 diabetes. SGLT-2 is extensively expressed throughout the CNS, and c-Fos expression was also observed within 2 hours of administration of SGLT-2is in mice. Recent clinical studies reported that SGLT-2is improved hypertension and atrial fibrillation by modulating the "overstimulated" renin-angiotensin-aldosterone system (RAAS) and suppressing the sympathetic nervous system (SNS) by directly/indirectly acting on the rostral ventrolateral medulla. Despite extensive research into the central mechanism of GLP-1RAs and SGLT-2is, the penetration of the blood-brain barrier (BBB) remains controversial. This review discusses the interaction between GLP-1RAs and SGLT-2is and the BBB to induce pharmacological effects via the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“drugs like semaglutide have been shown to affect areas of the brain involved in the regulation of appetite and reward-seeking behaviors, including the hypothalamus, which can be exposed to semaglutide through tanycytes lining the ventricle wall that may help to regulate eating behaviors, thus contributing to an overall reduction in energy intake [15,16].”
From What Is Food Noise? A Conceptual Model of Food Cue Reactivity (2023) · cites this paper as [16]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785 · cited 6×
“Additionally, the activities of enzymes, transporters, and cytoskeleton proteins on BBB microvessels are preferentially suppressed in these DIO animals.110,111 Moreover, a study indicated that a high-energy (HE) diet is related to increased BBB permeability as elevations in peripheral proinflammatory cytokines comprom…”
BackgroundInfluentialSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
Zheng, Y., Ley, S. H., & Hu, F. B. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.151 · Cited by 5,697 · cited 1×
“T2DM is a metabolic disorder characterized by long-term hyperglycemia and is one of the leading causes of morbidity and mortality.(1)”
BackgroundStructure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126 · cited 1×
“Accumulating evidence demonstrates that obesity is not only strongly related to the etiology and pathogenesis of T2DM but also to the development of diabetic complications.(2) Hyperglycemia and”
BackgroundZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
The gut flora as a forgotten organ
O'Hara, A. M., & Shanahan, F. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400731 · Cited by 2,791
The gut microbiota influences blood-brain barrier permeability in mice
Braniste, V., Al-Asmakh, M., Kowal, C., Anuar, F., Abbaspour, A., Tóth, M., Korecka, A., Bakocevic, N., Ng, L. G., Kundu, P., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009759 · Cited by 2,530
A molecular atlas of cell types and zonation in the brain vasculature
Vanlandewijck, M., He, L., Mäe, M. A., Andrae, J., Ando, K., Del Gaudio, F., Nahar, K., Lebouvier, T., Laviña, B., Gouveia, L., et al. (2018) · Nature · doi:10.1038/nature25739 · Cited by 1,892 · cited 1×
“However, a study of single-cell RNA sequencing in the brain shows that the presence of GLP-1R on BBB endothelial cells is negligible.(37) Exenatide,(38) lixisenatide,(39,40) beinaglutide,(41) liraglutide,(42) dulagutide(43) and semaglutide(44) are now commercially accessible as GLP-1 receptor agonists (Table 1).”
BackgroundSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868 · cited 3×
“Although providing a first glimpse at the capacity of GLP-1RAs and SGLT-2is to traverse the BBB, the current review has not disclosed the specific signaling mechanisms, particularly for SGLT-2is.”
BackgroundInfluential
Research works printed but not linked: 2
- Bhavsar, 2013, Curr Diabetes Rev, 9, 161, 10.2174/1573399811309020007 · doi:10.2174/1573399811309020007 · Paper page
- Larsen, 1997, Endocrinology, 138, 4445, 10.1210/endo.138.10.5270 · DOI · Paper page
Cited by
Albumin-based delivery systems: Recent advances, challenges, and opportunities
Murphy, G., Brayden, D. J., Cheung, D. L., Liew, A., Fitzgerald, M. T., & Pandit, A. S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.035 · Cited by 119
GLP-1 Receptor Agonist Use and Risk of Suicide Death
Ueda, P., Söderling, J., Wintzell, V., Svanström, H., Pazzagli, L., Eliasson, B., Melbye, M., Hviid, A., & Pasternak, B. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.4369 · Cited by 103
Hölscher, C. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109952 · Cited by 108
Bruns VI, N., Tressler, E. H., Vendruscolo, L. F., Leggio, L., & Farokhnia, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107312 · Cited by 89
De Giorgi, R., Ghenciulescu, A., Dziwisz, O., Taquet, M., Adler, A. I., Koychev, I., Upthegrove, R., Solmi, M., McCutcheon, R., Pillinger, T., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00390-x · Cited by 77
What Is Food Noise? A Conceptual Model of Food Cue Reactivity
Hayashi, D., Edwards, C., Emond, J. A., Gilbert-Diamond, D., Butt, M., Rigby, A., & Masterson, T. D. (2023) · Nutrients · doi:10.3390/nu15224809 · Cited by 80
“…the brain involved in the regulation of appetite and reward-seeking behaviors, including the hypothalamus, which can be exposed to semaglutide through tanycytes lining the ventricle wall that may help to regulate eating behaviors, thus contributing to an overall reduction in energy intake [15,16].”
BackgroundVulnerability of the Hippocampus to Insults: Links to Blood–Brain Barrier Dysfunction
Davidson, T. L., & Stevenson, R. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041991 · Cited by 90
Arillotta, D., Floresta, G., Papanti Pelletier, G. D., Guirguis, A., Corkery, J. M., Martinotti, G., & Schifano, F. (2024) · Brain Sciences · doi:10.3390/brainsci14060617 · Cited by 64
Farokhnia, M., Tazare, J., Pince, C. L., Bruns, N., Gray, J. C., Re, V. L., Fiellin, D. A., Kranzler, H. R., Koob, G. F., Justice, A. C., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci188314 · Cited by 72
GLP-1 programs the neurovascular landscape
Chen, B., Yu, X., HORVATH-DIANO, C., Ortuño, M. J., Tschöp, M. H., Jastreboff, A. M., & Schneeberger, M. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.003 · Cited by 62
Marquez-Meneses, J. D., Olaya-Bonilla, S. A., Barrera-Carreño, S., Tibaduiza-Arévalo, L. C., Forero-Cárdenas, S., Carrillo-Vaca, L., Rojas-Rodríguez, L. C., Calderón‐Ospina, C., & Rodríguez, J. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115338 · Cited by 57
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
Devasia, A. G., Ramasamy, A., & Leo, C. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041778 · Cited by 48
GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential
Moaket, O. S., Obaid, S. E., Obaid, F. E., Shakeeb, Y. A., Elsharief, S. M., Tania, A., Darwish, R., Butler, A. E., & Moin, A. S. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110743 · Cited by 46
Lengsfeld, S., Probst, L., Emara, Y., Werlen, L., Vogt, D., Bathelt, C., Baur, F., Caviezel, B., Vukajlovic, T., Fischer, M., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105284 · Cited by 40
GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
Złotek, M., Kurowska, A., Herbet, M., & Piątkowska‐Chmiel, I. (2023) · Biomedicines · doi:10.3390/biomedicines11113035 · Cited by 32
Liao, L., Zhang, L., Yang, C., Wang, T., Feng, L., Peng, C., Long, Y., Dai, G., Chang, L., Yan, W., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106598 · Cited by 28
Kuthati, Y., Davuluri, V. N. G., & Wong, C. (2025) · Biomolecules · doi:10.3390/biom15050622 · Cited by 32
Semaglutide treatment of hypothalamic obesity – a real-life data study
Svendstrup, M., Rasmussen, A. K., Kistorp, C., Klose, M., & Andreassen, M. (2024) · Pituitary · doi:10.1007/s11102-024-01429-5 · Cited by 23
New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
Hung, C., & Lu, L. (2024) · Neurology International · doi:10.3390/neurolint16060124 · Cited by 24
Teixeira, L. C. R., Luizon, M. R., & Gomes, K. B. (2025) · Receptors · doi:10.3390/receptors4010002 · Cited by 31
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
Vercalsteren, E., Karampatsi, D., Buizza, C., Nyström, T., Klein, T., Paul, G., Patrone, C., & Darsalia, V. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02174-6 · Cited by 25
Targeting the GLP-2 receptor in the management of obesity
Pálsson, T. G., Gilliam‐Vigh, H., Jensen, B. A. H., Jeppesen, P. B., Lund, A., Knop, F. K., & Nielsen, C. K. (2024) · Peptides · doi:10.1016/j.peptides.2024.171210 · Cited by 26
GLP-1 in the Hypothalamic Paraventricular Nucleus Promotes Sympathetic Activation and Hypertension
Xu, X., Wang, J.-X., Chen, J.-L., Dai, M., Wang, Y., Chen, Q., Li, Y., Zhu, G., & Chen, A. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.2032-23.2024 · Cited by 25
Hölscher, C. (2025) · CNS Drugs · doi:10.1007/s40263-025-01226-z · Cited by 30
Magdy, Y., Kamar, S. A., Habib, M. Z., Rady, H. Y., Rabei, M. R., & Khedr, S. A. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06834-7 · Cited by 24
Scheen, A. J. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101474 · Cited by 22
Vilarrasa, E., Nicolau, J., de la Cueva, P., Goday, A., Gallardo, F., Martorell, A., & Carrascosa, J. M. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.06.017 · Cited by 28
Khan, T. T. S., Sheikh, Z., Maleknia, S. D., Oveissi, F., Fathi, A., Abrams, T., Ong, H. X., & Traini, D. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2387110 · Cited by 20
Lin, Y., Wu, J., Lee, M.-C., Su, C.-Y., Toh, H. S., Chang, W., Chen, S.-Y., Kuo, F., Tang, H., & Liao, C. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae093 · Cited by 20
Abdelaziz, H. A., Hamed, M. F., Ghoniem, H. A., Nader, M. A., & Suddek, G. M. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-024-10162-6 · Cited by 18
Acetyl-CoA carboxylase activation disrupts iron homeostasis to drive ferroptosis
Han, Z., Han, S., Fang, X., Lu, M., Mao, Y., Shi, L., Song, J., Wang, T., Xiao, J., Xiang, L., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.05.421 · Cited by 15
Sabbagh, M. N., Cummings, J. L., Ballard, C. G., van der Flier, W. M., Heneka, M. T., Holst, J. J., Knudsen, L. B., Salloway, S., Tansey, M. G., & Drucker, D. J. (2025) · Nature Aging · doi:10.1038/s43587-025-01029-3 · Cited by 17
Dong, M., Chen, H., Wen, S., Yuan, Y., Yang, L., Li, Y., Yuan, X., Xu, D., & Zhou, L. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s399367 · Cited by 20
Self-citationAbubakar, M., Nama, L., Ansari, M. M., Ansari, M. M., Bhardwaj, S., Daksh, R., Syamala, K. L. V., Jamadade, M. S., Chhabra, V., Kumar, D., et al. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266293416240515075450 · Cited by 18
Glucagon-like peptide-1 receptor agonism and end-organ protection
Daniels, S. J., Karlsson, C., Schrauwen, P., & Parker, V. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.01.002 · Cited by 20
Pradhan, S. P., Sahu, P. K., & Behera, A. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04696-1 · Cited by 14
Recent Advances in Understanding the Molecular Mechanisms of SGLT2 Inhibitors in Atrial Remodeling
Minciună, I., Tomoaia, R., Mihăilă, M.-D., Cismaru, G. L., Puiu, M., Roşu, R., Simu, G. R., Frîngu, F. I., Irimie, D. A., Caloian, B., et al. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46090571 · Cited by 20
Ali, M. A., Michel, H. E., Menze, E. T., Tadros, M., & Wahdan, S. A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177525 · Cited by 12
GLP-1 Receptor Agonists in Breast Cancer: A New Frontier in Obesity and Prognosis Management
Xande, J. G., & del Giglio, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167744 · Cited by 14
Central and peripheral neural circuits regulating glucose homeostasis
Espinoza, D., Seibold, F., & Stanley, S. A. (2025) · npj Biomedical Innovations. · doi:10.1038/s44385-025-00036-8 · Cited by 17
Babazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 16
Translational research on cognitive impairment in chronic kidney disease
Wagner, C. A., Massy, Z. A., Capasso, G., Mattace-Raso, F., Pépin, M., Bobot, M., Zoccali, C., Ferreira, A. C., Hoorn, E. J., Silva, P. H. I., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae229 · Cited by 16
Targeting Neurodegeneration with SGLT2is: From Molecular Mechanisms to Clinical Implications
Asadinejad, H., Taherkhani, S., Golboos, S. M., Azizi, Y., & Mohammadkhanizadeh, A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05457-5 · Cited by 11
Vilarrasa, E., Nicolau, J., de la Cueva, P., Goday, A., Gallardo, F., Martorell, A., & Carrascosa, J. M. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.10.019 · Cited by 8
Zhang, S., Huang, Y., Han, C., Wang, F., Chen, M., Yang, S., Yang, S., & Wang, C. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113711 · Cited by 10
Tang, H., Donahoo, W. T., DeKosky, S. T., Lee, Y. A., Svensson, M., Bian, J., & Guo, J. S. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70161 · Cited by 11
Mouhammad, Z. A., Rombaut, A., García-Bermúdez, M. Y., Vohra, R., Tribble, J. R., Williams, P. A., & Kolko, M. (2025) · Molecular Brain · doi:10.1186/s13041-025-01224-8 · Cited by 9
Emerging pharmacological targets for alcohol use disorder
Brockway, D. F., & Crowley, N. A. (2024) · Alcohol · doi:10.1016/j.alcohol.2024.07.007 · Cited by 6
Glucagon-Like Peptide-1 Receptor Agonists in Neurodegenerative Diseases: A Comprehensive Review
Ibrahim, R., Kambal, A., & Abdelmajeed, M. A. (2025) · Cureus · doi:10.7759/cureus.92441 · Cited by 11
GLP-1 Signalling as a Therapeutic Avenue in Parkinson’s Disease: A Comprehensive Review
Orozco, M. P., Rivadeneira, V. V., & León-Rojas, J. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412163 · Cited by 8
Glucagon-Like Peptide-1 Receptor Agonists for Mood Disorders and Suicide Risk
McIntyre, R. S. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.04.019 · Cited by 7
Toraih, E. A., Alenezy, A. K., Hussein, M. H., Hashmat, S., Mummadi, S., Alrawili, N. F., Abdelmaksoud, A., & Fawzy, M. S. (2025) · Biomedicines · doi:10.3390/biomedicines13051049 · Cited by 8
A Comprehensive Review of Membrane Transporters and MicroRNA Regulation in Alzheimer’s Disease
Mishra, S., Stany, B. K., Das, A., Deepankumar, K., & Vijayan, M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04135-2 · Cited by 5
Samanidou, V., Tsamis, K., Ceasovschih, A., Koufakis, T., Patoulias, D., Rizos, E. C., Rizzo, M., Milionis, H. J., & Barkas, F. (2026) · Journal of Central Nervous System Disease · doi:10.1177/11795735261444425 · Cited by 4
Sahoo, S. K., Paidesetty, S. K., Sahu, P. K., Pattanaik, S., & Dandela, R. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109129 · Cited by 5
Zoubiri, H., Saiah, W., Otmane, A., Saidi, H., Makrelouf, M., Abderrahman, S. A., Haddam, A. E. M., & Koceir, E.-A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031218 · Cited by 3
Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes
Abbasi, M., Sun, K., Huggins, K. W., Heath, B., DeLoit, H., McGinness, L., & Mccamy, K. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.035 · Cited by 10
Omari, M. B., Naseri, S., & Hassan, A. J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s448670 · Cited by 3
Xu, Z., Wen, S., Dong, M., & Zhou, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16146 · Cited by 4
Self-citationGlucagon-like peptide-1 and impaired counterregulatory responses to hypoglycemia in type 1 diabetes
Rocha, G. R., & de Melo, F. F. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.99928 · Cited by 4
Lu, F., Li, E., Gao, Y., Zhang, Y., Kong, L., & Yang, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16202 · Cited by 4
Abdel-Lah, E. S., Hamad, N., Taha, A. F., Mohamed, W. H., Fawy, M. A., Attaai, A., Abbas, F. Y. A., Sherkawy, H. S., Abdelwarith, A. M., & Gamea, M. G. (2025) · Drug Development Research · doi:10.1002/ddr.70180 · Cited by 3
Repurposing immunomodulatory drugs targeting microglia for amyotrophic lateral sclerosis
Maes, K. J. H., & Briedé, J. J. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150032 · Cited by 6
Progress on exercise therapy in type 2 diabetes mellitus with cognitive impairment
Xiang, Y., Zhao, Y., Huang, L., & Zhou, J. (2026) · Frontiers in Sports and Active Living · doi:10.3389/fspor.2026.1742195 · Cited by 3
The effects of glucagon-like peptide-1 receptor agonists on sympathetic neuron activity
Koyanagi, Y., Iigaya, K., Ikeda, K., Onimaru, H., & Izumizaki, M. (2026) · Hypertension Research · doi:10.1038/s41440-026-02633-5 · Cited by 4
Šiarnik, P., Rádiková, Ž., Kollár, B., Kutšálová, M., Penesová, A., Havranová, A., Imrich, R., Vlček, M., Žitňanová, I., Krastev, G., et al. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-00982-4 · Cited by 2
Washio, T., Hissen, S. L., Takeda, R., Akins, J. D., Wakeham, D. J., Brazile, T. L., Hearon, C. M., MacNamara, J. P., Sarma, S., Levine, B. D., et al. (2024) · Clinical Autonomic Research · doi:10.1007/s10286-023-01013-0 · Cited by 2
Cheng, H., Jing, Y., Xu, C., Chen, M., Su, H., Yang, X., & Zhang, L. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s567851 · Cited by 2
Association Between GLP-1 RAs and Idiopathic Intracranial Hypertension
Manzano-Hernández, L., Vázquez, M. M., & Jiménez, D. L. (2026) · JAMA Neurology · doi:10.1001/jamaneurol.2026.0001 · Cited by 1
Qi, L., Kang, H., Li, X., Wang, L., Lin, Y., Zhan, M., Zeng, F., Xiao, Z., Liu, X., Chen, Z., et al. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1705784 · Cited by 1
Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-β42 Aggregation
Fallot, L. B., Anderson, C. A., Pinc, J. R., Stevenson, A., Schleck, M. C., Hawryschuk, E., Li, O. Z., Palchak, J. C., Toole, J. R., Kubiak, R. W., II, et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c01289 · Cited by 2
Floresta, G., Arillotta, D., Catalani, V., Pelletier, G. D. P., Corkery, J., Guirguis, A., & Schifano, F. (2024) · Scientia Pharmaceutica · doi:10.3390/scipharm92020017 · Cited by 3
Thompson, G. J. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70033 · Cited by 2
The Neuroprotective Effects of GLP-1 Analogues on Alzheimer's Disease – A Literature Review
Ulicka, W., Dudek, P., Łuczak, K., Chudzikowski, M., Pawlik, A., Pięta, J., Tabeau, A., Sitarek, H., Prus, J., & Prokopiuk, A. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.80.59398 · Cited by 1
Effects of Obesity on Human Health and the Emerging Role of GLP-1 Based Therapies
Bansal, G. (2025) · International journal of high school research · doi:10.36838/v7i3.10
Elfaki, E. M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Eliwa, D., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.10.045
Direct consequences of diabetes on the nervous system: structural and molecular pathological changes
Mendes, O. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00003-7
Di, J., Yang, X., He, X., Cao, Z., & Guo, Y. (2026) · Medicine · doi:10.1097/md.0000000000047355
Association Between GLP-1 RAs and Idiopathic Intracranial Hypertension—Reply
Sioutas, G. S., Reavey-Cantwell, J. F., & Rivet, D. J. (2026) · JAMA Neurology · doi:10.1001/jamaneurol.2026.0004
Mahatme, R. J., Moore, S. A., Gangavaram, A., Muthusamy, N., Bernholt, D. L., & Grawe, B. M. (2026) · Cureus · doi:10.7759/cureus.110874
Mir, M. A., Nabi, S. U., Mir, R. A., Ali, S. I., Noorani, I. A., Muzzaffar, S., & Khurshid, I. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02547-w
Baldwin, K., Lau, A., Ignaszewski, M. J., Wong, J. S. H., Azar, P., & Siu, J. T. P. (2026) · Journal of Dual Diagnosis · doi:10.1080/15504263.2026.2720402
Jucha, J., Zając, D., Darasz, D., Łukawski, A., Slobozheniuk, L., Bieniak-Pentchev, M., Kaczorek, M., Machnik, K., Dziewięcka, O., & Ziębka, W. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6010
Macesic, M. V., Lalic, K. S., Lukić, L., Milicic, T. J., Stojmenović, G. M., Stojković, T., Gajović, J. S., Stoiljkovic, M. M., Milin-Lazovic, J. S., Milovancevic, M. M., et al. (2026) · Diabetology · doi:10.3390/diabetology7090186
SGLT2i NEUROPROTECTIVE PROPERTIES IN DEPRESSION, AUTISM SPECTRUM DISORDER AND EPILEPSY
Zając, D., Darasz, D., Jucha, J., Ochońska, I., Dziewięcka, O., Ziębka, W., Żołyński, M., Kaczorek, M., Machnik, K., & Łobaziewicz, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6321
Cubitt, M., Ellenbroek, B. A., & Haase, A. M. (2026) · Biomolecules · doi:10.3390/biom16101397
Devi, D., Rani, A., Singh, J., Quasmi, M. N., Jangra, A., & Kumar, D. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02731-y
GLP‐1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications
Ueda, P. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70170
Findeis, J., Koschker, A., & Winterholler, M. (2026) · Epilepsia · doi:10.1002/epi.70527
Metadata
- Authors
- Dong, M., Wen, S., & Zhou, L.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Corresponding author
- Zhou, Ligang
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2022-08
- Volume
- Volume 15
- Pages
- 2583-2597
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC9417299
- OpenAlex
- W4292553261
- Cited by
- 90
- References
- 122
- Citations by year
- 2026: 24 · 2025: 34 · 2024: 25 · 2023: 7
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Natural Science Foundation of Shanghai (ZHYY-ZXYJHZX-2-201712, PWR12014-06, 21675034, 19ZR1447500, 81370932)
- Wenzhou Medical University
- National Natural Science Foundation of China (81370932, PWR12014-06, 19ZR1447500, PWZzk2017-03, ZHYY-ZXYJHZX-2-201712, 21675034)
- Fudan University (Zdzk2020-24)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- blood-brain barrier, GLP-1 receptor agonists, SGLT2 inhibitors, type 2 diabetes, central nervous system, Fos expression, food intake regulation, paraventricular nucleus, renin-angiotensin-aldosterone system, sympathetic nervous system, hypertension, atrial fibrillation, chronic heart failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.